SEC Form 4 · accession 0001140361-17-008884
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan W Ayers
Officer — Chairman, President & CEO · Director
Period of report
Feb 22, 2017
Accepted (ET)
Feb 23, 2017 · 6:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2017 | M | 2,286 | $43.71 | A | 995,947 | D | |
| Common Stock | Feb 22, 2017 | M | 50,000 | $38.795 | A | 1,045,947 | D | |
| Common StockF1 | Feb 22, 2017 | S | 31,795 | $142.5484 | D | 1,014,152 | D | |
| Common StockF2 | Feb 22, 2017 | S | 3,205 | $142.8419 | D | 1,010,947 | D | |
| Common Stock | holding | — | — | — | 98,000 | I | by Ayers Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right-to-buy)F5,F3 | $43.71 | Feb 22, 2017 | M | 2,286 | D | — | Feb 13, 2019 | Common Stock | 2,286 | 0 | D |
| Non-Qualified Stock Option (right-to-buy)F5,F4 | $38.795 | Feb 22, 2017 | M | 50,000 | D | — | Feb 13, 2018 | Common Stock | 50,000 | 40,000 | D |
Explanation of responses
- F1Represents the weighted average sales price of the shares sold ranging from a low of $141.80 to a high of $142.795 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $142.80 to a high of $143.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Grant of option to buy 1,143 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2017, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F4Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016, The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F5Not applicable.